ABIONYX Pharma Provides an Update on Its Activity and Its Cash Position for the 4th Quarter 2022
28 Februar 2023 - 6:41PM
Business Wire
- 2022 consolidated revenue of €5.3 million, net of studies
for Abionyx
- Continued clinical development in renal diseases following
positive clinical results from the Phase 2a RACERS study in
Sepsis
- Cash position of €4.0 million as of December 31,
2022
- Biotech strategy in ophthalmology to be announced during the
month of March 2023
Regulatory News:
ABIONYX Pharma, (FR0012616852 - ABNX - eligible for PEA
PME) (Paris:ABNX), a new generation biotech company dedicated
to the discovery and development of innovative therapies for
patients, today provides an update on its activity and cash
position as of December 31, 2022.
Selected financial information (IFRS)
M€
2022
2021
Revenue from ABIONYX Pharma
0.00
0.03
Revenue from IRIS Pharma
5.25
0.64*
Total revenue
5.25
0.67
Other revenue
0.00
0.04
Total revenue income and
revenue
5.25
0.71
Cash and cash equivalents at the end of
the period
4.04
7.93
* Revenue from IRIS Pharma over 1 month in 2021 due to the
acquisition date
ABIONYX Pharma recorded a consolidated revenue of €5.25 million
for the financial year 2022 after elimination of intra-group
transactions. IRIS Pharma recorded an annual revenue of €5.75
million, of which €4.49 million in preclinical and €1.26 million in
clinical. Since its integration more than a year ago, IRIS Pharma
has focused part of its Services activity on preclinical studies of
bio-HDL in ophthalmology, in order to determine the strategic axes
to accelerate its development.
Regarding the biotech activity dedicated to the discovery and
development of innovative therapies to improve the lives of
patients, the company did not generate any revenue in this
financial year because, in line with its purpose, the company
provided its bioproduct free of charge as part of the compassionate
access applications.
Update on biotech activity
In the renal area, the Phase 2a clinical trial for CER-001
(called RACERS) in sepsis at high risk of developing acute kidney
injury, conducted in partnership with the University of Bari,
produced major positive clinical results announced in January. The
clinical study met both primary and secondary endpoints. There is
no approved treatment for sepsis, which is the 3rd leading cause of
death worldwide and affects nearly 14 million people each year,
regardless of age or country. Moreover, with an ageing population,
the number of patients is expected to double by 2050.
In the LCAT orphan disease, the company continues to receive new
Compassionate Access Authorisation (CAA) requests for bio-HDL
(CER-001) from several hospitals around the world.
In ophthalmology, the company will present its strategy during
the month of March.
The company reminds that beyond the existing cash balance of
€4.0 million, no dilutive financial instruments have been put in
place, as the company favors looking for a strategic
partnership.
About ABIONYX Pharma
ABIONYX Pharma is a new generation biotech company that aims to
contribute to health through innovative therapies in indications
where there is no effective or existing treatment, even the rarest
ones. Thanks to its partners in research, medicine,
biopharmaceuticals and shareholding, the company innovates on a
daily basis to propose drugs for the treatment of renal and
ophthalmological diseases, or new HDL vectors used for targeted
drug delivery.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230228006224/en/
NewCap Investor Relations Louis-Victor Delouvrier Nicolas
Fossiez abionyx@newcap.eu +33 (0)1 44 71 98 53
NewCap Media Relations Arthur Rouillé abionyx@newcap.eu
+33 (0)1 44 71 00 15
Abionyx Pharma (EU:ABNX)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Abionyx Pharma (EU:ABNX)
Historical Stock Chart
Von Apr 2023 bis Apr 2024